# Therapeutic potential of exerkines in neurodegenerative and mental disorders: a narrative review

**Authors:** Suwol Yang, Hye-Won Sang, Seoyeon Kim, Eun-Jeong Cho, Youngju Choi, Dong Woo Kang, Young C. Jang, Dong-Ho Park, Hyo-Bum Kwak, Jang Soo Yook

PMC · DOI: 10.3389/fphys.2026.1793043 · 2026-03-19

## TL;DR

This review explores how molecules released during exercise, called exerkines, may help treat brain disorders like Alzheimer's and depression by improving brain health.

## Contribution

The paper provides a comprehensive review of exerkines' roles in neurodegenerative and mental disorders, focusing on preclinical findings and future therapeutic directions.

## Key findings

- Exerkines like BDNF, irisin, and IL-6 can cross the blood-brain barrier and improve brain function.
- Exerkines modulate the brain microenvironment and reduce neuroinflammation.
- Rodent studies show exerkines promote neurogenesis and synaptic plasticity.

## Abstract

Neurodegenerative and mental disorders impose significant global disease burdens and pose serious social and economic challenges. Physical exercise (PE) exerts beneficial effects on brain health, contributing to a reduction in the risk of Alzheimer’s disease (AD), Parkinson’s disease (PD), depression, anxiety, and post-traumatic stress disorder (PTSD). To understand these effects of PE, a variety of molecules released from various tissues in response to PE have been discovered, which are collectively called ‘exerkines’. In particular, the skeletal muscle acts as an endocrine organ, secreting exerkines and is included in the category of myokines that facilitate direct or indirect crosstalk between the muscle and the brain. Although muscles actively interact with organs such as the liver, pancreas, and adipose tissue, the precise mechanisms of muscle–brain communication have yet to be fully elucidated. In the skeletal muscle, the types of exerkines secreted and their effects vary depending on the PE modality. Furthermore, these exerkines can cross the blood-brain barrier (BBB) to exert direct effects or act indirectly via molecular signaling pathways, contributing to the modulation of the brain microenvironment, attenuation of neuroinflammation, and neurodegeneration. Previous studies have indicated that brain-derived neurotrophic factor (BDNF), irisin, cathepsin B (CTSB), interleukin-6 (IL-6), and insulin-like growth factor 1 (IGF-1) are involved in enhancing cognitive performance and improving behavioral outcomes by promoting neurogenesis and synaptic plasticity. This review comprehensively discusses the effects of exerkines on the brain and the physiological responses manifested in neurodegenerative and mental disorders focusing primarily on findings from rodent models. Based on these insights, this review proposes future research directions to translate preclinical findings into therapeutic strategies.

## Linked entities

- **Proteins:** BDNF (brain derived neurotrophic factor), IL6 (interleukin 6), IGF1 (insulin like growth factor 1), CTSB (cathepsin B)
- **Diseases:** Alzheimer’s disease (MONDO:0004975), Parkinson’s disease (MONDO:0005180), depression (MONDO:0002050), anxiety (MONDO:0005618), post-traumatic stress disorder (MONDO:0005146)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** CTSB (cathepsin B) [NCBI Gene 1508] {aka APPS, CPSB, KWE, RECEUP}, FNDC5 (fibronectin type III domain containing 5) [NCBI Gene 252995] {aka FRCP2, irisin}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}
- **Diseases:** PTSD (MESH:D013313), depression (MESH:D003866), PD (MESH:D010300), neuroinflammation (MESH:D000090862), AD (MESH:D000544), anxiety (MESH:D001007), Neurodegenerative and mental disorders (MESH:D019636)
- **Chemicals:** exerkines (-)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13043392/full.md

---
Source: https://tomesphere.com/paper/PMC13043392